The bioTROOP Study: A Multiomic Bioanalysis of the Trauma Resuscitation with Group O Whole Blood Or Products (TROOP) trial
Abstract
Severe blood loss (hemorrhage) after traumatic injury is a leading cause of death both on and off the battlefield. Blood transfusions are the primary treatment for bleeding trauma patients, with the goal being to stop bleeding and restore circulating blood volume. Currently, donated whole blood that is used for transfusions is separated into components of red blood cells (RBC), plasma and platelets and multiple units of each blood component are transfused separately (an approach that is known as component therapy CT). However, there is some evidence to suggest that transfusion of whole blood (WB) may be better than CT for saving lives. A randomized clinical trial, called the TROOP trial, is currently underway to determine whether resuscitation with WB improves survival. Understanding why there is a difference between the two approaches is important. Therefore, we are proposing a companion study to the TROOP trial, called the bioTROOP study, that will collect blood samples from enrolled participants in the minutes, hours and days following transfusion in order to evaluate the patient response to WB compared to CT. The bioTROOP study will perform blood-based measurements to determine whether WB impacts mechanisms that regulate bleeding and clot formation in injured patients that could make it better than CT. We will also measure metabolic and immune responses that occur after injury and determine whether WB may lessen abnormal responses that often lead to clinical complications, such as organ damage, sepsis or abnormal blood clots. We will collect DNA from patients to assess common gene mutations that could help explain differences in the way that people respond to trauma or WB transfusion. Finally, we will also determine whether a new, freeze-dried platelet product, Thrombosomes (TBX), is capable of promoting clot formation in blood that is collected from injured patients prior to massive transfusion. In these studies, TBX will not be transfused to patients, but the information that we learn about TBX will inform whether TBX could be used in the future as a treatment to help stop bleeding in injured patients. The bioTROOP study is an unprecedented opportunity to gain new insights into transfusion strategies used to treat bleeding trauma patients. Findings from this study will contribute new knowledge regarding the human response to trauma, bleeding and resuscitation. This information will benefit the worldwide trauma community, both in military and civilian settings, and help optimize transfusion approaches to increase survival from severe bleeding caused by traumatic injury.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Jan 04, 2024
- Source ID
- HT94252311014
Entities
People
- Jillian R Richter
Organizations
- United States Army
- University of Alabama at Birmingham